ABSTRACT

Introduction: Gout is the most prevalent inflammatory crystal arthropathy worldwide and is a chronic disease requiring strict, lifelong adherence to drug therapy and healthy lifestyles. Gout has a heavy burden on the patient’s sexual health, owing to the associated inflammatory status, long-term complications, and chronic pain; however, the effects of gout also extend to the partner’s sexual health.

Aims: We aimed to investigate how the presence of a partner could influence the complex interaction between risk factors for sexual dysfunctions in gout in order to define novel strategies to improve sexual health and disease management.

Methods: Clinical and experimental data on the role of the couple in chronic diseases, as well as on the association between gout and sexual health, were searched through Pubmed.

Main outcome measures: Evidence from studies describing how the presence of a couple and leveraging sexual health can improve management and clinical outcomes for chronic diseases.

Results: Treatment adherence can improve the sexual health of gout patients and their partners; likewise, by leveraging sexual health, it would be possible to promote better health-seeking behaviors, ultimately improving gout management.

Clinical implications: Promoting awareness of the sexual health relevance of gout can potentially be a pivotal strategy to improve disease management and prevent the progression of sexual dysfunctions from subclinical to overt forms.

Strengths and limitations: Identifying a bidirectional association between sexual health and disease management paves the way for improved disease control and can potentially prevent the development of sexual dysfunctions in couples affected by gout. However, the relevance of the couple has not been adequately addressed in gout management, and most evidence comes from other chronic diseases.

Conclusion: Improving gout management results in better sexual health, and vice-versa promoting better sexual health can improve disease control for gout. The presence of a partner improves the behavioral well-being of gout patients, with beneficial effects on both sexual health and gout management. Sansone A, Reisman Y, Meto S, et al. The Role of the “Anti-Inflammatory” Couple for the Management of Hyperuricemia With Deposition. Sex Med 2022;10:100562.

Copyright © 2022, International Society of Sexual Medicine. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
individuals could afford a “rich” diet heavy in meat. To the present date, being this disease more easily found in marginal lifestyles adopting trash food, alcohol abuse, and lacking physical activity, it cannot be consistently considered a disease of the elites. Undoubtedly, changes in socioeconomic milieu may have had a profound impact on its prevalence between 1990 and 2017, the rates of gout both globally and in China were increasing, but with a significantly larger extent for males in China than globally. This was proportional to the adoption of Western lifestyles, mirrored by an increased average body mass index.

Gout is a typical non-communicable chronic disease (NCD), generated by important genetic and predisposing factors, but also associated with socio-demographic characteristics (age, gender) and the behaviors mentioned above, and not rarely comorbid with other NCDs (metabolic, renal and cardiovascular diseases, etc.). Gout is a chronic condition potentially leading to decreased mobility, persistent pain, and impaired quality of life. Several studies have provided evidence of how gout can impair health-related quality of life (HR-QoL). This impairment may be due to its disease-specific features such as excruciatingly painful attacks, their frequency and the number of joints involved, pain in between attacks, long-term joint damage due to accumulation of tophi, or, when the untreated disease progresses to more severe forms, to the amputation. A US veterans study found that gout was associated with poorer HR-QoL, functional limitation, higher mortality, and increased primary care visits and inpatient utilization. Hence, gout is not only a metabolic disease but has important psychosocial aspects that may dramatically affect its impact and final clinical outcome.

Although only recently considered as a part of the general one, sexual health could be regarded as a marker of the psychosocial milieu associated with NCDs in general and of gout in particular and, at the same time, a marker of the consequences of gout itself. Not only do the underlying shared risk factors (such as aging, sedentary lifestyle, obesity, metabolic syndrome, and hypertension) potentially contribute to an impaired sexual life, but also gout itself can potentially have devastating effects on the patient’s ability to have intercourse. In the present narrative review, we aim to focus on aspects of hyperuricemia with deposition that should be considered in order to increase awareness of the potential risks for sexual health, not only in the affected patients but also in their partners. We also aim to discuss literature suggesting that the involvement of the couple in the clinical management of gout can potentially improve patient care and prevent, or delay, the onset of sexual dysfunctions; at the same time, promoting sexual health in such patients can be a crucial strategy to improve clinical outcomes and disease management. This paper will therefore start with a “primer” on gout pathophysiology before moving to the actual burden of gout on the couple, to the beneficial and adverse effects of a partner (or loss thereof) on compliance to gout therapy, to the consequences of gout on sexual health as well as on the general and sexual quality of life and, finally, to the potential strategies involving sexual health to promote better lifestyles.

Literature Search Strategy

Peer-reviewed publications were identified through a PubMed search using the search terms “sexual dysfunction”, “erectile dysfunction”, “premature ejaculation”, “gout”, “chronic disease”, “couple”, and “hyperuricemia”. The search was completed in May 2022 and was limited to articles published in English. Relevant articles were identified based upon the expertise and clinical experience of the authors. Additional papers were retrieved by reviewing references from cited works.

Gout: a brief primer.

Gout is a disease resulting from the deposition of monosodium urate (MSU) crystals in target organs and tissues, which occurs when the concentration of serum uric acid (UA) increases over the 6.8 mg/dl solubility threshold. Several environmental factors can also affect the actual threshold for the deposition of MSU crystals, including temperature and pH. Not all individuals with hyperuricemia develop crystal deposition or the consequent acute inflammatory response; additional factors, such as genetics, underlying inflammatory background, or pre-existing fiber damage, can potentially affect the mechanisms leading to the progression from silent hyperuricemia to asymptomatic crystal deposition, and subsequently to acute gout flares and chronic gouty arthritis. In fact, the prevalence of hyperuricemia in the US population is more than 3.5 times higher than that of gout, proving that the presence of elevated serum UA is not enough to result in the development of the disease.

Gout is also characterized by a relapsing-remitting course, with extended times of silent hyperuricemia interspersed with intermittent episodes of acute crystal-associated inflammatory arthritis. During these periods of “intercritical gout”, the MSU crystals persist in the target organs and tissues: the inflammatory response is toned down, but chemokines persist, suggesting that low-grade inflammation is still present following the resolution of the acute phase. Moreover, there is growing experimental evidence that supports a relationship between high concentrations of UA and endothelial dysfunction, a typical target of a number of chronic inflammations.

The main goals of the medical treatment of gout include minimizing the inflammation and pain of an acute gout attack, and preventing future gout flares by lowering serum UA levels. Xanthine oxidase inhibitors (XOIs), including allopurinol and febuxostat, are first-line agents for the prevention of acute attacks. Uricosuric agents are an appropriate adjunctive therapy or second-line agent when XOIs are contraindicated or poorly tolerated. Recently, several third-line agents (e.g., pegloticase) have become available for the treatment of refractory gout.

Despite a good pharmacological efficacy and tolerability, as in the majority of the chronic treatments for NCDs, treatment adherence is remarkably poor for gout patients, even worse
than in other chronic diseases. This can be possibly due to the relapsing-remitting course of the disease, which might give some patients the false belief of being from disease, despite being in one of the intercritical periods. Another possible explanation for the poor treatment adherence lies in the possible combination of lacking “tangible” effects and the presence of side effects. Antihypertensive drugs are a paramount example of this mechanism: hypertension, by itself, can often be asymptomatic, whereas side effects from several antihypertensive treatments are frequent and can impair QoL. Education and behavioral interventions have often been considered among the possible strategies available to clinicians to improve this negative scenario, but with limited efficacy.

Gout, the “Third Wheel” in the Couple: Issues and Challenges

Gout is almost twice as prevalent in men than in women and, as with the majority of NCDs, is strictly associated with other unmodifiable factors, such as genetics and age, with prevalence steadily increasing in elderly individuals. However, modifiable factors also play a major role. A recent study demonstrated that, compared to age-matched controls, male gout patients are significantly more likely to be overweight or obese, to have diabetes and hypertension, and to have more health-risk behaviors, such as binge-drinking, previous use of tobacco products, and sedentary lifestyle. Interestingly, all the mentioned aspects are well-known major risk factors for sexual dysfunction, particularly erectile dysfunction (ED). While research on the relationship between female gout and female sexual dysfunction is still in its infancy, the epidemiology and risk factors make, in principle, gout a condition primarily affecting male sexual function. However, it would be reductive to consider only the affected patient as an individual whose sexual health has been impaired by gout: indeed, the partner is also facing, indirectly, the burden of the disease. For the sake of simplicity, let’s consider a heterosexual couple in which the male partner is affected by gout, and the female partner is relatively healthy. The first gout flare, being a sudden event with few (if any) premonitory signs, is potentially a source of concern and anxiety for both members of the couple—even more if the flare occurs at the wrong time, e.g., during celebration times (when flare-triggering, purine-containing foods and beverages are likely to abound). The resulting distress is expected to affect the couple—or, rather, the “dyad”—before diagnosis and in the subsequent weeks of uncertainty following treatment onset. Anxiety is a powerful trigger for sexual dysfunction in men and women and can therefore worsen the couple’s sexual health. As such, it becomes clear that while gout is—in this case— affecting only half of the couple, both partners have to face the likely consequences in terms of intimacy.

Following ULT initiation, lifestyle changes are also likely required to reduce the chances of relapse and, at the same time, can potentially be beneficial for the couple’s sexual health. For example, the Mediterranean diet, rich in fiber, antioxidants, and mono-unsaturated fatty acids, can improve UA levels and reduce inflammatory status and oxidative stress. The same diet has improved erectile function. Likewise, physical exercise has beneficial effects on gout as well on male and female sexual health and function, possibly also mediated by its effect on body weight and inflammatory status: the effects of physical exercise on the endocrine milieu can promote a favorable anti-inflammatory profile, increasing levels of anti-inflammatory cytokines (such as IL-10) and reducing levels of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β positively acting on both gout and sexual health. In fact, to simplify, gout produces chronic and acute inflammation, both major pathogenetic mechanisms of sexual dysfunction. Also, for this reason, Park and coll. correctly proposed that all gout patients should be assessed for ED. This tenable advice is fortified by the concept that the couple’s sexual health could act as an “anti-inflammatory” mechanism positively affecting gout itself and its inflammatory consequences with respect to the adherence to both lifestyle changes and the prescribed pharmacological treatments.

May the Marital Life Modify Therapeutical Compliance and Adherence?

Compliance and adherence to lifestyle changes in gout are often poor due to limited awareness of purine-rich foods and beverages or to the physical disability limiting physical exercise during gout flares and chronic arthropathy. Additionally, during intercritical periods, the perception of having “overcome” the disease can also be a further reason for poor treatment adherence: treatment compliance (including strict and careful observance of the prescribed lifestyle changes) is usually higher for acute rather than chronic diseases and is particularly low for gout. The presence of a partner can be beneficial in these regards. In fact, according to the “theory of social causation”, being married is accompanied by better health behaviors and greater attention to individual well-being. This becomes even more pronounced for gout, as the preventive effects are more likely to occur in men than in women. In several chronic lifestyle-related diseases, such as the many NCDs, the presence of a partner can increase adherence to prevention and treatment, with married couples having better compliance. The shared responsibilities improve treatment outcomes and adherence to therapy, as proven in chronic conditions. Positive partners act, in fact, as “reminders” for treatment continuation and can motivate their significant others to maintain healthy behaviors, as proven by the lower cardiovascular risk and mortality associated with marital status. Surprisingly, the potential role of the partner has not been adequately addressed by studies investigating treatment adherence in gout. In a vicious circle, gout impairs sexual health, which can in turn progressively worsen self-care, and leads to partner distancing, resulting in worse adherence to treatment which ultimately promotes the progression of both sexual dysfunctions and gout itself (Figure 1).
Effects of Partner Loss and Distancing on Sex-Gout Outcomes

On the contrary, conflicts in the couple are likely to affect treatment compliance negatively,68 and the loss of a partner is associated with worse health outcomes.65 Several reasons for the preventive effects of the couple have been hypothesized: marriage is associated with a shorter delay in seeking medical treatment, and the presence of a partner also results in better economic, behavioral, mental, and emotional well-being.65,69 The emotional distress due to partner loss can influence the inflammatory phenotype driving depression pathogenesis70: the same inflammatory cytokines TNF-α, IL-6, and IL-1, whose concentration is also regulated by testosterone levels,56 are involved in the immune response occurring in gout flares. Therefore, losing a partner has adverse effects from both a behavioral and a biochemical point of view on the gouty inflammation and its management.

When extreme, this mechanism is well recognized as the “Widowhood effect”, i.e., the increased morbidity and the decreased male survival following the death of a spouse.71–74 Elegantly, Corona et al. demonstrated that the absence of a partner or their lacking sexual interest in a patient with ED produces delayed referral to andrology clinics, late assessment of ED comorbidities, more risky behaviors, and, as a final consequence, more inflammation and more NCDs.75

It is worth mentioning, however, that the loss of a partner does not exclusively mean their passing. Negative effects on different health outcomes occur even following divorce.76 The association between sexual health and divorce is a complex one: while indeed sexual dysfunctions are a relatively frequent factor involved in marriage breakdown,77 it is also true that they might be consequences of a dysfunctional relationship,36,78,79 in which the “partner stress” (i.e., marital conflict68) can ease progression from subclinical80,81 to overt, clinically manifest sexual dysfunction.82

As stated, TNF-α, IL-6, and IL-1 are involved in the immune response to the loss of a partner. These cytokines also have a role in the development of sexual dysfunction, most notably ED,83,84 by inducing endothelial dysfunction and reducing nitric oxide availability. To an extent, this low-grade inflammation is mediated by several proinflammatory agents, which further contribute to worsening sexual health for both men and women.85,86,17 In summarizing: the inflammatory status prominently featured in gout is exacerbated by further “inflammatory” psycho-social factors, such as lack of partner’s interest, partner loss, and consequent depression, which can worsen sexual health. All such determinants are mutually associated, and measures aimed at preserving sexual health can, by transforming the “inflammatory” couple into the “anti-inflammatory” one, be a key strategy to improve outcomes for all other underlying conditions.

Diagnosing and Curing the Couple’s Gout-Related Sexual Dysfunctions

For all these reasons, we recommend exploring the couple’s sexual life in all patients with gout. This could be easily done by well-validated psychometric tools, as reported in Table 1.87 In this perspective, it is crucial to make all possible efforts to explore not only each partner individually but also the couple as a unit. Based on the initial screening, sexual function could be investigated by focused physical examination and laboratory and instrumental tests aiming to identify the severity of the symptom (subclinical, mild, moderate, severe), to identify the comorbidity with other sexual dysfunctions, to find other comorbid NCDs and risk factors, and to ascertain the impact of the sexual symptom in the general QoL and in the mood of the couple itself.79

On these bases, a tailored therapy is always advised, starting from the transformation of vicious into virtuous lifestyles (i.e., smoking cessation, quitting illegal drugs, reducing alcohol dramatically, shifting to healthier diets, and increasing physical activity) and then addressing other possible needs (i.e., prescribing testosterone in hypogonadal patients or psychotherapies for subjects with psychopathological traits).

Prescription of the gold therapeutical standard for ED, i.e., type 5 phosphodiesterase inhibitors (PDE5Is), is highly advised in the subject with gout and inability or reduced capacity to obtain or maintain the erection in the presence of proper erotic stimuli.88 This therapy needs to be tailored to the couple’s clinical profile.89,90 While PDE5Is do not display any particular warning concerning gout or relative therapies,91 some patients may be better prescribed with the PDE5i with the best safety profile, such as avanafil,92,93 others with the drug with the best vascular properties, such as sildenafil,94 also in its newest orodispersible, intimacy sparing, pharmacological form,95,96 and others with the long-acting tadalafl either in the on-demand regimen, as used for the other PDE5Is, or in the low-dose, daily regimen, peculiar for this drug.97

Interestingly, a significant positive correlation has been found between PDE5I use and allopurinol, hydrochlorothiazide, nicotine, and alcohol use confirming that ED is a major problem in gout, hypertension, smoking, and drinking, respectively, but also
indirectly suggesting the safety of the association of PDE5I with the mentioned drugs and substances in these real-life contexts.98

Both diagnosis and therapy of ED, or other couple’s sexual symptoms, may have further advantages. Careful screening of sexual health gives the doctor “baseline” evidence, useful for the follow-up of the chronic disease itself. Although yet to be demonstrated, progressive improvement or worsening of the metabolic profile may be mirrored by parallel changes in sexual health. In diabetes, another metabolic NCD sharing many risk factors and comorbidities with gout, this relationship is very strong, and erectile function is to be considered an efficient biomarker of diabetic complications and glycem control and vice versa.99,100 Studies are needed to ascertain the same in gout.

Moreover, a successful therapy of gout-related sexual dysfunction may also produce unexpected advantages for the treatment of gout itself, as discussed in the following paragraphs.

Improving Gout Management by Leveraging Sexual Health

There is ample evidence suggesting that sexual health can benefit many conditions, from psychological distress101 to general health.102 From a broader point of view, it is generally assumed that sexual health is also a reliable hallmark of cardiovascular and metabolic health and a predictor of future cardiovascular mortality.103–105 While most people having sexual dysfunctions do not immediately seek sexual health advice and treatment,106–108 the sudden onset of ED can potentially be the proverbial “canary in the coal mine”,109 predicting future cardiovascular events.110 This is unsurprising, given that sexual dysfunctions (ED in particular) and cardiovascular diseases share the same modifiable risk factors, such as sedentary lifestyle, obesity, smoking, and dyslipidemia.111,34 However, gout also shares many of these risk factors, and different guidelines have advocated lifestyle modifications for its clinical management.10 Such changes in daily behaviors are often difficult to maintain for gout patients, resulting in poor adherence10; however, providing sexual consultations to gout patients, and explaining the extent to which these interventions can promote better sexual health, could possibly improve patient compliance. Additionally, as one partner’s sexual health inevitably bears on the other’s and lifestyle interventions generally involve the couple, it would be beneficial to involve both members of the couple in sexological consultations.113

A typical representation of this concept is provided by the smoking habit in the couple and how the couple may dramatically improve the attempt to quit tobacco. While the first
Sexual and General Quality of Life in Gout Patients

Last but not least, it is mandatory to consider the possible negative effects of gout on the psychological status of the affected individual and, by extent, on their family members, especially the partner.

Gout has a significant impact on patients’ lives. Beyond pain and functional limitations, it increases anxiety and depressive disorders and affects sexual function, sleep, social relationships, emotional health, and work. Patients may feel helpless and frustrated and tend to social isolation. Shame, embarrassment, and stigma may lead to minimization of the impact of the disease.

Moreover, gout affects not only the patient’s quality of life but also the partner’s and other family members’. Dependency on the family members during flares or physical disability can be important.

Sex is an essential contributor to QOL, and the sexual quality of life of gout patients is negatively affected, as expected based on the presence of both organic and non-organic risk factors. Therefore, the sexual health of the couple is endangered, owing to the association between the two partners’ sexual function. Promoting compliance to treatment, including drug therapy and better lifestyles, would thus be beneficial to the sexual health of the couple: making both partners actively involved in the clinical management of gout by leveraging sexual health can result in improved quality of life for the couple.

Finally, addressing the sexual life of the couple may also have positive effects. Gout, along with other rheumatological diseases, such as osteoarthritis, fibromyalgia, rheumatoid arthritis, and low back pain, is a major driver of the use of illegal drugs (cocaine, hallucinogen, amphetamine, or sedative/anxiolytic/hypnotic) and alcohol. It is unclear how this figure precedes and may have a causal relationship or, on the contrary, may represent unmet needs or unsatisfied expectations of patients with rheumatic diseases. In any case, the same substances have a direct negative effect on the ability to obtain and maintain an erection, further reducing the level of the couple’s sexual QoL (SQoL). The clinical management of the sexual symptom in the couple would bona fide increase the therapeutic alliance with the partner in reducing these dysfunctional abuses, and further motivate the patient to follow the correct prescriptions more carefully, thus reducing the use of illegal substances and the abuse of alcohol.

Conclusion: the Anti-Inflammatory Couple

Hyperuricemia with deposition is a subtle and multifaceted disease that, after long periods of (apparent) clinical silence, manifests itself in a violent and potentially devastating way affecting the general quality of life of the patient and his partner but also, and specifically, of the quality of sex life.

It is a typical clinical picture named in Italy as “the dog eating its own tail”, which can be idiomatically translated in English as: “it’s a catch-22”. The patient with gout has impaired sexual life, and at the same time the subject with poor sexual health is much less motivated to adopt virtuous behaviors to prevent gout and to follow the long-term pharmacological therapy.

In this article, we aimed to prove the importance of sexual health as a powerful surrogate marker of the HR-QoL and of the couple as a powerful tool for prevention and for providing a solid reinforcement of motivation towards lifestyle improvement and for the correct use of drugs. In fact, romantic partners significantly influence their reciprocal health behaviors.

Patients seldom voluntarily mention sexual disorders to their clinicians, and unfortunately, many doctors are not educated in sexual medicine and therefore feel capable of interviewing neither the patient nor the partner about sexual symptoms. The patient perceives this lack of scientific and clinical interest in sexual function (biologically speaking, the most important of all) as a poor prognosis. When, on the contrary, the doctor motivates his patients to follow lifestyle changes or chronic therapies by suggesting that these can have very positive effects on sexual and marital life, therapeutic compliance is expected to improve and the patient, especially if not young, interprets the message of the doctor as a good prognosis. The patient perceives two positive signs: the first says that if the doctor is concerned about the sexual symptom, there is still a lot to do, and the second signal acts precisely as a formidable motivational element reinforced within, and by, the couple.

For the dog to really stop eating its tail, however, robust and direct scientific evidence correlating improved control of serum
UA (e.g., with febuxostat) to a reduced prevalence of sexual symptoms is needed. This will further prove that the couple is considered a powerful and effective “anti-inflammatory” therapeutic target, which increases and amplifies the drugs’ efficacy with adoption of a virtuous lifestyle and better adherence to prescriptions. At present, specific studies aimed at addressing the relationship between gout and sexual dysfunction are still missing. Likewise, there is insufficient evidence on the impact of gout on the couple’s quality of life. As gout shares many similarities with other chronic conditions, it can be assumed that a typical “phenotype” can affect sexual health outcomes for the couple. Still, more studies are needed to address this literature gap.

The bidirectional link between gout and sexual dysfunction, i.e., how gout can have negative consequences for sexual health and how acting on promoting healthy sexual life may improve clinical and therapeutic outcomes of gout, is, therefore, a promising new chapter of sexual medicine, in which research will continue more and more in the years to come.

**Corresponding Author:** Prof. Emmanuele A. Jannini, Chair of Endocrinology & Medical Sexology, Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier, 1, 00133 Rome, Italy; E-mail: eajannini@gmail.com

**Funding:** This work was supported by Menarini International Operations Luxembourg S.A. All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations.

**REFERENCES**

1. Cox P, Gupta S, Zhao SS, et al. The incidence and prevalence of cardiovascular diseases in gout: a systematic review and meta-analysis. *Rheumatol Int* 2021;41:1209–1219. doi: 10.1007/s00296-021-04876-6.

2. Park JS, Kang M, Song J-S, et al. Trends of Gout Prevalence in South Korea Based on Medical Utilization: A National Health Insurance Service Database (2002–2015). *J Rheumatic Diseases* 2020;27:174–181. doi: 10.4078/jrd.2020.27.3.174.

3. Kiadaliri AA, Englund M. Temporal trends and regional disparity in rheumatoid arthritis and gout hospitalizations in Sweden, 1998–2015. *Clin Rheumatol* 2018;37:825–830. doi: 10.1007/s10067-018-3983-8.

4. Lim SY, Lu N, Oza A, et al. Trends in Gout and Rheumatoid Arthritis Hospitalizations in the United States, 1993–2011. *JAMA* 2016;315:2345–2347. doi: 10.1001/jama.2016.3517.

5. Winnard D, Wright C, Taylor WJ, et al. National prevalence of gout derived from administrative health data in Aotearoa New Zealand. *Rheumatology (Oxford)* 2012;51:901–909. doi: 10.1093/rheumatology/ker361.

6. Kuo C-F, Yu K-H, See L-C, et al. Risk of myocardial infarction among patients with gout: a nationwide population-based study. *Rheumatology (Oxford)* 2013;52:111–117. doi: 10.1093/rheumatology/kes169.

7. Kuo C-F, Grainge MJ, Mallen C, et al. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. *Ann Rheum Dis* 2015;74:661–667. doi: 10.1136/annrheumdis-2013-204463.

8. Kuo C-F, Grainge MJ, See L-C, et al. Epidemiology and management of gout in Taiwan: a nationwide population study. *Arthritis Res Ther* 2015;17:13. doi: 10.1186/s13075-015-0522-8.

9. Chen-Xu M, Yokose C, Rai SK, et al. Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the national health and nutrition examination survey, 2007–2016. *Arthritis Rheumatol* 2019;71:991–999. doi: 10.1002/art.40807.

10. Dalbeth N, Choi HK, Joosten LAB, et al. Gout. *Nat Rev Dis Primers* 2019;5:69. doi: 10.1038/s41572-019-0115-y.

11. Tang YM, Zhang L, Zhu SZ, et al. Gout in China, 1990–2017: the global Burden of Disease Study 2017. *Public Health* 2021;191:33–38. doi: 10.1016/j.puhe.2020.06.029.

12. Roddy E, Choi HK. Epidemiology of Gout. *Rheumatic Dis Clin North Am* 2014;40:155–175. doi: 10.1016/j.rdc.2014.01.001.

13. Chandratre P, Roddy E, Clarson L, et al. Health-related quality of life in gout: a systematic review. *Rheumatology (Oxford)* 2013;52:2031–2040. doi: 10.1093/rheumatology/ket265.

14. Scirè CA, Manara M, Cimmino MA, et al. Gout impacts on function and health-related quality of life beyond associated risk factors and medical conditions: results from the KING observational study of the Italian Society for Rheumatology (SIR). *Arthritis Res Ther* 2013;15:R101. doi: 10.1186/ar4281.

15. Chandratre P, Mallen C, Richardson J, et al. Health-related quality of life in gout in primary care: Baseline findings from a cohort study. *Semin Arthritis Rheum* 2018;48:61–69. doi: 10.1016/j.semarthrit.2017.12.005.

16. Singh JA, Strand V. Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans. *Ann Rheum Dis* 2008;67:1310–1316. doi: 10.1136/ard.2007.081604.

17. Sansone A, Reisman Y, Jannini EA. Relationship between hyperuricemia with deposition and sexual dysfunction in males and females. *J Endocrinol Invest* 2022;1–13. doi: 10.1007/s10067-021-01719-w.

18. Chhana A, Lee G, Dalbeth N. Factors influencing the crystallization of monosodium urate: a systematic literature review. *BMC Musculoskeletal Disorders* 2015;16:296. doi: 10.1186/s12891-015-0762-4.

19. Loeb JN. The influence of temperature on the solubility of monosodium urate. *Arthritis Rheumatism* 1972;15:189–192. doi: 10.1002/art.1780150209.

20. Zhang W-Z. Why does hyperuricemia not necessarily induce Gout? *Biomolecules* 2021;11:280. doi: 10.3390/biom11020280.

21. Dalbeth N, Stamp L. Hyperuricaemia and gout: time for a new staging system? *Ann Rheum Dis* 2014;73:1598–1600. doi: 10.1136/annrheumdis-2014-205304.
22. Ragab G, Elshahaly M, Bardin T. Gout: An old disease in new perspective — A review. J Adv Res 2017;8:495–511. doi: 10.1016/j.jare.2017.04.008.

23. Mercuro G, Vitale C, Cerquetani E, et al. Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk. Am J Cardiol 2004;94:932–935. doi: 10.1016/j.amjcard.2004.06.032.

24. Maruhashi T, Hisatome I, Kihara Y, et al. Hyperuricemia and endothelial function: From molecular background to clinical perspectives. Atherosclerosis 2018;278:226–231. doi: 10.1016/j.atherosclerosis.2018.10.007.

25. Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 2017;76:29–42. doi: 10.1136/annrheumdis-2016-209707.

26. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487–497. doi: 10.1056/NEJMra050100.

27. Chan AHY, Horne R, Hankins M, et al. The medication adherence report scale: A measurement tool for eliciting patients’ reports of nonadherence. Br J Clin Pharmacol 2020;86:1281–1288. doi: 10.1111/bcpr.14193.

28. Ho GH, Pillinger MH, Toprover M. Adherence to gout guideline recommendations. J Rheumatol 2021;33:128–134. doi: 10.1097/BOR.0000000000000774.

29. Scheepers LEJM, van Onna M, Stehouwer CDA, et al. Medication adherence among patients with gout: A systematic review and meta-analysis. Semin Arthritis Rheum 2018;47:689–702. doi: 10.1016/j.semarthrit.2017.09.007.

30. Briesacher BA, Andrade SE, Fouayzi H, et al. Comparison of adherence to gout guideline recommendations. Clin Rheumatol 2016;21:233–234. doi: 10.1007/s10067-015-3087-0.

31. Dehlin M, Scheepers L, Landgren A, et al. Lifestyle factors and comorbidities in gout patients compared to the general population in Western Sweden: results from a questionnaire study. Scand J Rheumatol 2022;1–4. doi: 10.1080/03009742.2022.2035952.

32. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487–497. doi: 10.1056/NEJMra050100.

33. Dehlin M, Scheepers L, Landgren A, et al. Lifestyle factors and comorbidities in gout patients compared to the general population in Western Sweden: results from a questionnaire study. Scand J Rheumatol 2022;1–4. doi: 10.1080/03009742.2022.2035952.

34. Jannini EA. SM = SM: the interface of systems medicine and sexual medicine for facing non-communicable diseases in a gender-dependent manner. Sex Med Rev 2017;5:349–364. doi: 10.1016/j.jsexmed.2017.04.002.

35. Carosa E, Sansone A, Jannini EA. Management of endocrine disease: Female sexual dysfunction for the endocrinologist. Eur J Endocrinol 2020;182:R101. doi: 10.1530/EJE-19-0903.

36. Yafi FA, Jenkins L, Albersen M, et al. Erectile dysfunction. Nat Rev Dis Primers 2016;2:16003. doi: 10.1038/nrdp.2016.3.

37. Dewitte M, Bettocchi C, Carvalho J, et al. A psychosocial approach to erectile dysfunction: position statements from the European Society of Sexual Medicine (ESSM). Sex Med 2021;9:100434. doi: 10.1016/j.esxm.2021.100434.

38. Eltnerman DS, Bhattacharyya SK, Mafiolos M, et al. The quality of life and economic burden of erectile dysfunction. RRU 2021;13:79–86. doi: 10.2147/RRU.S283097.

39. Laurent SM, Simons AD. Sexual dysfunction in depression and anxiety: Conceptualizing sexual dysfunction as part of an internalizing dimension. Clin Psychol Rev 2009;29:575–585. doi: 10.1016/j.cpr.2009.06.007.

40. Kaplan HS. Anxiety and sexual dysfunction. J Clin Psychiatry 1988;49:21–25.

41. Burri A, Spector T, Rahman Q. The etiological relationship between anxiety sensitivity, sexual distress, and female sexual dysfunction is partly genetically moderated. J Sex Med 2012;9:1887–1896. doi: 10.1111/j.1743-6109.2012.02710.x.

42. Mollaioi D, Ciocca G, Limoncin E, et al. Lifestyles and sexual health in men and women: the gender perspective in sexual medicine. Reprod Biol Endocrinol 2018;16:108. doi: 10.1186/s12958-018-0437-8.

43. Stamostergiou J, Theodoridis X, Ganochoriti V, et al. The role of the Mediterranean diet in hyperuricemia and gout. Medit J Rheumatol 2018;29:21–25. doi: 10.31138/mjr.29.1.21.

44. Esposito K, Giugliano F, Maiorino MI, et al. Dietary factors, Mediterranean diet and erectile dysfunction. J Sex Med 2010;7:2338–2345. doi: 10.1111/j.1743-6109.2010.01842.x.

45. La J, Roberts NH, Yafi FA. Diet and men’s sexual health. Sex Med Rev 2018;6:54–68. doi: 10.1016/j.sxmr.2017.07.004.

46. Williams PT. Effects of diet, physical activity and performance, and body weight on incident gout in ostensibly healthy, vigorously active men. Am J Clin Nutr 2008;87:1480–1487.

47. Sansone A, Sansone M, Vaamonde D, et al. Sport, doping and male fertility. Reprod Biol Endocrinol 2018;16:114. doi: 10.1186/s12958-018-0435-x.

48. La Vignera S, Condorelli RA, Cannarella R, et al. Sport, doping and female fertility. Reprod Biol Endocrinol 2018;16:108. doi: 10.1186/s12958-018-0437-8.

49. Maggio M, Basaria S, Ceda GP, et al. The relationship between testosterone and molecular markers of inflammation in older men. J Endocrinol Invest 2005;28:116–119.

50. Mohamad N-V, Wong SK, Wan Hasan WN, et al. The relationship between circulating testosterone and inflammatory cytokines in men. Aging Male 2019;22:129–140. doi: 10.1080/13685538.2018.1482487.
Hyperuricemia with Deposition and Couple's Sexual Health

52. Park K, Gupta NK, Olweny EO, et al. Beyond arthritis: understanding the influence of gout on erectile function: a systematic review. *Urology* 2021;153:19–27. doi: 10.1016/j.urology.2020.12.005.

53. Harrold LR, Mazor KM, Peterson D, et al. Patients’ knowledge and beliefs concerning gout and its treatment: a population based study. *BMC Musculoskeletal Dis* 2012;13:180. doi: 10.1186/1471-2474-13-180.

54. ten Klooster PM, Vonkeman HE, Oude Voshaar MAH, et al. Experiences of gout-related disability from the patients’ perspective: a mixed methods study. *Clin Rheumatol* 2014;33:1145–1154. doi: 10.1007/s10067-013-2400-6.

55. Reach G. Treatment adherence in patients with gout. *Joint Bone Spine* 2011;78:456–459. doi: 10.1016/j.jbspin.2011.05.010.

56. Molloy GJ, Stamatakis E, Randall G, et al. Marital status, gender and cardiovascular mortality: Behavioural, psychological distress and metabolic explanations. *Soc Sci Med* 2009;69:223–228. doi: 10.1016/j.socscimed.2009.05.010.

57. Lee CS, Tan JHM, Sankari U, et al. Assessing oral medication adherence among patients with type 2 diabetes mellitus treated with polytherapy in a developed Asian community: a cross-sectional study. *BMJ Open* 2017;7:e016317. doi: 10.1136/bmjopen-2017-016317.

58. Reading SR, Black MH, Singer DE, et al. Risk factors for medication non-adherence among atrial fibrillation patients. *BMC Cardiovascular Dis* 2019;19:38. doi: 10.1186/s12872-019-1019-1.

59. Rosen RC, Seftel AD, Ruff DD, et al. A pilot study using a web survey to identify characteristics that influence hypogonadal men to initiate testosterone replacement therapy. *Am J Mens Health* 2018;12:567–574. doi: 10.1177/1557988315625773.

60. Pan J, Hu B, Wu L, et al. The effect of social support on treatment adherence in patients with gout. *Joint Bone Spine* 2011;78:456–459. doi: 10.1016/j.jbspin.2011.05.010.

61. Molloy GJ, Stamatakis E, Randall G, et al. Marital status, gender and cardiovascular mortality: Behavioural, psychological distress and metabolic explanations. *Soc Sci Med* 2009;69:223–228. doi: 10.1016/j.socscimed.2009.05.010.

62. Gianotten WL. Sexual aspects of shared decision making and couple-oriented interventions for chronic illness. *Ann Behav Med* 2010;40:325–342. doi: 10.1007/s12160-010-9216-2.

63. Martire LM, Schulz R, Helgeson VS, et al. Review and meta-analysis of couple-oriented interventions for chronic illness. *Ann Behav Med* 2010;40:325–342. doi: 10.1007/s12160-010-9216-2.

64. Martire LM, Stephens MAP, Mogle J, et al. Daily spousal influence on physical activity in knee osteoarthritis. *Ann Behav Med* 2013;45:213–223. doi: 10.1007/s12160-012-9442-x.

65. Wong CW, Kwok CS, Narain A, et al. Marital status and risk of cardiovascular diseases: a systematic review and meta-analysis. *Heart* 2018;104:1937–1948. doi: 10.1136/heartjnl-2018-313005.

66. Schultz WM, Hayek SS, Samman Tahhan A, et al. Marital status and outcomes in patients with cardiovascular disease. *J Am Heart Assoc* 2017;6:e005890. doi: 10.1161/JAHA.117.005890.

67. Manfredini R, De Giorgi A, Tiseo R, et al. Marital status, cardiovascular diseases, and cardiovascular risk factors: a review of the evidence. *J Womens Health (Larchmt)* 2017;26:624–632. doi: 10.1089/jwh.2016.6103.

68. Molloy GJ, Perkins-Porras L, Strike PC, et al. Social networks and partner stress as predictors of adherence to medication, rehabilitation attendance, and quality of life following acute coronary syndrome. *Health Psychol* 2008;27:52–58. doi: 10.1037/0278-6133.27.1.52.

69. Kravdal Ø, Wørn J, Reme B-A. Mental health benefits of cohabitation and marriage: A longitudinal analysis of Norwegian register data. *Popul Stud (Camb)* 2022;1–20. doi: 10.1080/03009332.2022.2063933.

70. Slavich GM, Irwin MR. From stress to inflammation and major depressive disorder: a social signal transduction theory of depression. *Psychol Bull* 2014;140:774–815. doi: 10.1037/a0035302.

71. Helsing KJ, Szkl M, Comstock GW. Factors associated with mortality after widowhood. *Am J Public Health* 1971;71:802–809. doi: 10.2105/ajph.71.8.802.

72. Umberson D. Family status and health behaviors: social control as a dimension of social integration. *J Soc Behav* 1987;28:306–319.

73. Waite LJ. Does marriage matter? *Demography* 1995;32:483–507.

74. Dupre ME, Beck AN, Meadows SO. Marital trajectories and mortality among US adults. *Am J Epidemiol* 2009;170:546–555. doi: 10.1093/aje/kwp194.

75. Corona G, Bandini E, Fisher A, et al. Psychobiological correlates of women’s sexual interest as perceived by patients with erectile dysfunction. *J Sex Med* 2010;7:2174–2183. doi: 10.1111/j.1743-6109.2010.01812.x.

76. Bourassa KJ, Cornelius T, Birk JL. Bereavement is associated with mortality after widowhood. *Am J Epidemiol* 2009;170:546–555. doi: 10.1093/aje/kwp194.

77. Gravningen K, Mitchell KR, Wellings K, et al. Reported reasons for breakdown of marriage and cohabitation in Britain: Findings from the third National Survey of Sexual Attitudes and Lifestyles (Natsal-3). *PLoS One* 2017;12:e0174429. doi: 10.1371/journal.pone.0174429.

78. Cabral PUL, Canário ACG, Spyrides MHC, et al. Determinants of sexual dysfunction among middle-aged women. *Int J Gynaecol Obstet* 2013;120:271–274. doi: 10.1016/j.ijo.2012.09.023.

79. Mulhall JP, Giraldi A, Hackett G, et al. The 2018 revision to the process of care model for evaluation of erectile dysfunction. *J Sex Med* 2018;15:1280–1292. doi: 10.1016/j.jsxm.2018.06.005.
80. Jannini EA, Lenzi A, Isidori A, et al. Subclinical erectile dysfunction: proposal for a novel taxonomic category in sexual medicine. J Sex Med 2006;3:787–794. doi: 10.1111/j.1743-6109.2006.00287.x.

81. Colonnello E, Ciocca G, Limoncin E, et al. Redefining a sexual medicine paradigm: subclinical premature ejaculation as a new taxonomic entity. Nat Rev Urol 2021;18:115–127. doi: 10.1038/s41585-020-00417-1.

82. Burgio G, Giammusso B, Calogero AE, et al. Evaluation of the mistakes in self-diagnosis of sexual dysfunctions in 11,000 male outpatients: a real-life study in an andrology clinic. J Clin Med 2019;8:1679. doi: 10.3390/jcm8101679. J Clin Med 2019;8:1679. doi: 10.3390/jcm8101679.

83. Carneiro FS, Webb RC, Tostes RC. Emerging role for TNF-α in erectile dysfunction. J Sex Med 2010;7:3823–3834. doi: 10.1111/j.1743-6109.2010.01762.x.

84. Rodrigues FL, Fais RS, Tostes RC, et al. There is a link between erectile dysfunction and heart failure: it could be inflammation. Curr Drug Targets 2015;16:442–450. doi: 10.2174/1389450116666150420145757.

85. Vlachopoulos C, Rokkas K, Ioakeimidis N, et al. Inflammation, metabolic syndrome, erectile dysfunction, and coronary artery disease: common links. Eur Urol 2007;52:1590–1600. doi: 10.1016/j.euro.2007.08.004.

86. Lorenz TK. Interactions between inflammation and female sexual desire and arousal function. Curr Sex Health Rep 2019;11:287–299. doi: 10.1007/s11930-019-00218-7.

87. Corona G, Jannini EA, Maggi M. Inventories for male and female sexual dysfunctions. Int J Impot Res 2006;18:236–250. doi: 10.1038/sj.ijir.3901410.

88. Burnett AL, Nehra A, Breau RH, et al. Erectile dysfunction: AUA guideline. J Urol 2018;200:633–641. doi: 10.1016/j.juro.2018.05.004.

89. Jannini EA, Sternbach N, Limoncin E, et al. Health-related characteristics and unmet needs of men with erectile dysfunction: a survey in five European countries. J Sex Med 2014;11:40–50. doi: 10.1111/j.1365-2605.2005.00590.x.

90. Corona G, Maggi M, Jannini EA. EDEUS, a real-life study on the users of phosphodiesterase type 5 inhibitors: prevalence, perceptions, and health care-seeking behavior among European men with a focus on 2nd-generation avanafil. Sex Med 2018;6:15–23. doi: 10.1016/j.jsxm.2017.10.003.

91. Schick P, Sager M, Wegner F, et al. Application of the gastro-duo as an in vitro dissolution tool to simulate the gastric emptying of the postprandial stomach. Mol Pharm 2019;16:4651–4660. doi: 10.1021/acs.molpharmaceut.9b00799.

92. Corona G, Rastrelli G, Burri A, et al. The safety and efficacy of Avanafil, a new 2(nd) generation PDE5i: comprehensive review and meta-analysis. Expert Opin Drug Saf 2016;15:237–247. doi: 10.1517/147440338.2016.1130126.

93. Corona G, Rastrelli G, Burri A, et al. First-generation phosphodiesterase type 5 inhibitors dropout: A comprehensive review and meta-analysis. Androl 2016;4:1002–1009. doi: 10.1111/andr.12255.

94. Jannini EA, Isidori AM, Gravina GL, et al. The ENDOTRIAL study: a spontaneous, open-label, randomized, multicenter, crossover study on the efficacy of sildenafil, tadalafil, and vardenafil in the treatment of erectile dysfunction. J Sex Med 2009;6:2547–2560. doi: 10.1111/j.1743-6109.2009.01375.x.

95. Scaglione F, Donde S, Hassan TA, et al. Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction: pharmacology and clinical impact of the sildenafil citrate oro-dispersible tablet formulation. Clin Ther 2017;39:370–377. doi: 10.1016/j.clinthera.2017.01.001.

96. Jannini EA, Droupy S. Needs and expectations of patients with erectile dysfunction: an update on pharmacological innovations in phosphodiesterase type 5 inhibition with focus on sildenafil. Sex Med 2019;7:1–10. doi: 10.1016/j.jsxm.2018.10.005.

97. Carosa E, Lombardo F, Martini P, et al. The therapeutic dilemma: how to use tadalafil. Int J Androl 2005;7:49–80 28 Suppl 2. doi: 10.1111/j.1365-2605.2005.00590.x.

98. Shao X-T, Zhang P-Y, Liu S-Y, et al. Assessment of correlations between sildenafil use and comorbidities and lifestyle factors using wastewater-based epidemiology. Water Res 2022;218:118446. doi: 10.1016/j.watres.2022.118446.

99. Sansone A, Mollaiali D, Ciocca G, et al. Sexual dysfunction in men and women with diabetes: a mirror of their complications? Curr Diab Rev 2021. doi: 10.2174/1573399817666210309104740.

100. Hu WS, Lin CL. Using progression in adapted diabetes complications severity index score to predict erectile dysfunction in men affected by type 2 diabetes mellitus. Postgrad Med J 2022 postgradmedj-2022-141557. doi: 10.1136/postgradmedj-2022-141557.

101. Mollaiali D, Sansone A, Ciocca G, et al. Benefits of sexual activity on psychological, relational, and sexual health during the COVID-19 breakout. J Sex Med 2021;18:35–49. doi: 10.1016/j.jsxm.2020.10.008.

102. Jannini EA, Fisher WA, Bitzer J, et al. Is sex just fun? How sexual activity improves health. J Sex Med 2009;6:2640–2648. doi: 10.1111/j.1743-6109.2009.01477.x.

103. Salonia A, Capogrosso P, Clementi MC, et al. Is erectile dysfunction a reliable indicator of general health status in men? Arab J Urol 2013;11:203–211. doi: 10.1016/j.aju.2013.07.008.

104. Corona G, Rastrelli G, Isidori AM, et al. Erectile dysfunction and cardiovascular risk: a review of current findings. Expert Rev Cardiovasc Ther 2020;18:155–164. doi: 10.1080/14779072.2020.1745632.

105. Yannas D, Frizza F, Vignozzi L, et al. Erectile dysfunction is a hallmark of cardiovascular disease: unavoidable matter of fact or opportunity to improve men’s health? J Clin Med 2021;10:2221. doi: 10.3390/jcm10102221.
106. Hinchliff S, Lewis R, Wellings K, et al. Pathways to help-seeking for sexual difficulties in older adults: qualitative findings from the third National Survey of Sexual Attitudes and Lifestyles (Natssal-3). Age Ageing 2021;50:546–553. doi: 10.1093/ageing/afa281.

107. Gott M, Hinchliff S. Barriers to seeking treatment for sexual problems in primary care: a qualitative study with older people. Fam Pract 2003;20:690–695. doi: 10.1093/fampra/cmg612.

108. Ezhova I, Savidge L, Bonnett C, et al. Barriers to older adults seeking sexual health advice and treatment: A scoping review. Int J Nurs Stud 2020;107:103566. doi: 10.1016/j.ijnurstu.2020.103566.

109. Meldrum DR, Gambone JC, Morris MA, et al. The link between erectile and cardiovascular health: the canary in the coal mine. Am J Cardiol 2011;108:599–606. doi: 10.1016/j.amjcard.2011.03.093.

110. Corona G, Forti G, Maggi M. Why can patients with erectile dysfunction be considered lucky? The association with testosterone deficiency and metabolic syndrome. Aging Male 2008;11:193–199. doi: 10.1080/13685530802468497.

111. Guay AT. ED2: erectile dysfunction = endothelial dysfunction. Endocrinol Metabolism Clin N Am 2007;36:453–463. doi: 10.1016/j.ecl.2007.03.007.

112. Masero I, Fanni E, Mannucci E, et al. Which are the male factors associated with female sexual dysfunction (FSD)? Androl 2016;4:911–920. doi: 10.1111/andr.12224.

113. Dean J, Rubio-Aurioles E, McCabe M, et al. Integrating partners into erectile dysfunction treatment: improving the sexual experience for the couple. Int J Clin Pract 2008;62:127–133. doi: 10.1111/j.1742-1241.2007.01636.x.

114. Sansone A, Limoncin E, Colonello E, et al. Harm reduction in sexual medicine. Sex Med Rev 2021. doi: 10.1016/j.sxmr.2021.01.005.

115. Berli C, Ochsner S, Stadler G, et al. Volitional processes and daily smoking: examining inter- and intradividual associations around a quit attempt. J Behav Med 2015;38:306–317. doi: 10.1007/s10865-014-9598-x.

116. Berli C, Lüscher J, Luszczynska A, et al. Couples’ daily self-regulation: the health action process approach at the dyadic level. PLoS One 2018;13:e0205887. doi: 10.1371/journal.pone.0205887.

117. Schwarzer R. Modeling health behavior change: how to predict and modify the adoption and maintenance of health behaviors. Appl Psychol 2008;57:1–29. doi: 10.1111/j.1464-0597.2007.00325.x.

118. Singh JA. The impact of gout on patient’s lives: a study of African-American and Caucasian men and women with gout. Arthritis Res Ther 2014;16:R132. doi: 10.1186/ar4589.

119. Lindsay K, Gow P, Vanderpyl J, et al. The experience and impact of living with gout: a study of men with chronic gout using a qualitative grounded theory approach. J Clin Rheumatol 2011;17:1–6. doi: 10.1097/RHU.0b013e318204a8f9.

120. Seow LL, Jiao N, Wang W, et al. A qualitative study exploring perceptions of patients with gout. Clin Nurs Res 2020;29:56–65. doi: 10.1177/105477381769219.

121. Singh JA. Gout and sexual function: patient perspective of how gout affects personal relationships and intimacy. BMC Rheumatol 2019;3:8. doi: 10.1186/s41927-019-0056-9.

122. Corona G, Petrone L, Mannucci E, et al. Assessment of the relational factor in male patients consulting for sexual dysfunction: the concept of couple sexual dysfunction. J Androl 2006;27:795–801. doi: 10.2164/jandrol.106.000638.

123. Nelson CJ. The impact of male sexual dysfunction on the female partner. Curr Sex Health Rep 2006;3:37–41. doi: 10.1007/s11930-006-0025-3.

124. Chew PY, Choy CL, Sidi H bin, et al. The association between female sexual dysfunction and sexual dysfunction in the male partner: a systematic review and meta-analysis. J Sex Med 2021;18:99–112. doi: 10.1016/j.jsxm.2020.10.001.

125. Singh JA. Time-trends in cocaine, hallucinogen, amphetamine, and sedative/anxiolytic/hypnotic use disorder hospitalizations in rheumatic diseases: a national time-trends study. Clin Rheumatol 2021;40:3007–3014. doi: 10.1007/s10067-021-05715-6.

126. Singh JA. Epidemiology and outcomes of alcohol use hospitalizations in people with gout, rheumatoid arthritis, fibromyalgia, osteoarthritis, or low back pain: a national US Study. J Clin Rheumatol 2022;28:e375–e380. doi: 10.1097/RHU.00000000000007731.

127. Labbate LA. Psychotropics and sexual dysfunction: the evidence and treatments. Adv Psychosom Med 2008;29:107–130. doi: 10.1159/000126627.

128. Valeiro C, Matos C, Scholl J, et al. Drug-induced sexual dysfunction: an analysis of reports to a national pharmacovigilance database. Drug Saf 2022. doi:10.1007/s40264-022-01174-3.

129. Jannini EA, Reisman Y. Medicine without sexual medicine is not medicine: An MJCSM and ESSM petition on sexual monitoring response to treatment in clinical practice. J Sex Med 2019;16:943–945. doi: 10.1016/j.jsxm.2019.04.001.

130. Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997;49:822–830. doi: 10.1016/S0090-4295(97)00238-0.

131. Ramanathan R, Mulhall J, Rao S, et al. Predictive correlation between the International Index of Erectile Function (IIEF) and Sexual Health Inventory for Men (SHIM): implications for calculating a derived SHIM for clinical use. J Sex Med 2007;4:1336–1344. doi: 10.1111/j.1743-6109.2007.00576.x.

132. Mulhall J, Althof SE, Brock GB, et al. Erectile dysfunction: monitoring response to treatment in clinical practice—recommendations of an international study panel. J Sex Med 2007;4:448–464. doi:10.1111/j.1743-6109.2007.00441.x.

133. Rosen R, Brown C, Heiman J, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 2000;26:191–208. doi: 10.1080/009262300278597.
134. Isidori AM, Pozza C, Esposito K, et al. Development and validation of a 6-item version of the female sexual function index (FSFI) as a diagnostic tool for female sexual dysfunction. *J Sex Med* 2010;7:1139–1146. doi: 10.1111/j.1743-6109.2009.01635.x.

135. Limoncin E, Tomassetti M, Gravina GL, et al. Premature ejaculation results in female sexual distress: standardization and validation of a new diagnostic tool for sexual distress. *J Urol* 2013;189:1830–1835. doi: 10.1016/j.juro.2012.11.007.

136. Symonds T, Perelman MA, Althof S, et al. Development and validation of a premature ejaculation diagnostic tool. *Eur Urol* 2007;52:565–573. doi: 10.1016/j.eururo.2007.01.028.

137. Limoncin E, Gravina GL, Lotti F, et al. The Masturbation Erection Index (MEI): validation of a new psychometric tool, derived from the six-item version of the International Index of Erectile Function (IIEF-6) and from the Erection Hardness Score (EHS), for measuring erectile function during masturbation. *BJU Int* 2019;123:530–537. doi: 10.1111/bju.14560.

138. Xi Y, Zhang H, Colonnello E, Limoncin E. The masturbatory premature ejaculation diagnostic tool (MPEDT): A novel psychometric tool to evaluate premature ejaculation during masturbation. *Androl* 2022;10:333–339. doi: 10.1111/andr.13125.

139. Limoncin E, Lotti F, Rossi M, et al. The impact of premature ejaculation on the subjective perception of orgasmic intensity: validation and standardisation of the ‘Orgasmometer’. *Androl* 2016;4:921–926. doi: 10.1111/andr.12220.

140. Mollaioli D, Di Sante S, Limoncin E, et al. Validation of a visual analogue scale to measure the subjective perception of orgasmic intensity in females: The Orgasmometer-F. *PLoS One* 2018;13:e0202076. doi: 10.1371/journal.pone.0202076.

141. Petrone L, Mannucci E, Corona G, et al. Structured interview on erectile dysfunction (SIEDY): a new, multidimensional instrument for quantification of pathogenetic issues on erectile dysfunction. *Int J Impot Res* 2003;15:210–220. doi: 10.1038/sj.ijir.3901006.

142. Spanier GB. Measuring dyadic adjustment: New scales for assessing the quality of marriage and similar dyads. *J Marriage Family* 1976;38:15–28. doi: 10.2307/350547.